Genetics of long-term treatment outcome in bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 65, Issue , 2016, Pages 17-24

  Fabbri, Chiara ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bipolar disorder; Gene; Pathway analysis; Pharmacogenomics; Treatment response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BUNGAROTOXIN RECEPTOR; LEUCINE RICH REPEAT KINASE 2; METABOTROPIC RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROTROPHIN 3;

ARTICLE; AS1 GENE; BIPOLAR DISORDER; CHRNA7 GENE; CLINICAL PRACTICE; CNTNAP2 GENE; CONTROLLED STUDY; DEPTOR GENE; DFNB31 GENE; DISEASE SEVERITY; DNA POLYMORPHISM; GENE; GENE FUNCTION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE; GRIN2A GENE; GRIN2B GENE; GRM4 GENE; HUMAN; KCNJ2 GENE; MAJOR CLINICAL STUDY; MANIA; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NFYC GENE; NRXN1 GENE; NTF3 GENE; NTRK2 GENE; PHARMACOGENOMICS; PHENOTYPE; PROGNOSIS; QUALITY CONTROL; RASGRF1 GENE; RNLS GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SORCS2 GENE; TRAF3IP2 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE;

ADULT; BIPOLAR DISORDER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84940417318     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.08.008     Document Type: Article

References (79)

1. Abelaira H.M., Reus G.Z., Neotti M.V., Quevedo J. The role of mTOR in depression and antidepressant responses. Life Sci. 2014, 101:10-14.
2. Ancin I., Barabash A., Vazquez-Alvarez B., Santos J.L., Sanchez-Morla E., Martinez J.L., et al. Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with schizophrenia. Psychiatr. Genet. 2010, 20:289-297.
3. Ancin I., Cabranes J.A., Santos J.L., Sanchez-Morla E., Vazquez-Alvarez B., Rodriguez-Moya L., et al. CHRNA7 haplotypes are associated with impaired attention in euthymic bipolar disorder. J. Affect. Disord. 2011, 133:340-345.
4. Anderson C.A., Pettersson F.H., Clarke G.M., Cardon L.R., Morris A.P., Zondervan K.T. Data quality control in genetic case-control association studies. Nat. Protoc. 2010, 5:1564-1573.
5. Andreasen J.T., Redrobe J.P., Nielsen E.O. Combined alpha7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol. Biochem. Behav. 2012, 100:624-629.
6. Avramopoulos D., Lasseter V.K., Fallin M.D., Wolyniec P.S., McGrath J.A., Nestadt G., et al. Stage II follow-up on a linkage scan for bipolar disorder in the Ashkenazim provides suggestive evidence for chromosome 12p and the GRIN2B gene. Genet. Med. 2007, 9:745-751.
7. Barman A., Assmann A., Richter S., Soch J., Schutze H., Wustenberg T., et al. Genetic variation of the RASGRF1 regulatory region affects human hippocampus-dependent memory. Front. Hum. Neurosci. 2014, 8:260.
8. Baum A.E., Akula N., Cabanero M., Cardona I., Corona W., Klemens B., et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry 2008, 13:197-207.
9. Baum A.E., Hamshere M., Green E., Cichon S., Rietschel M., Noethen M.M., et al. Meta-analysis of two genome-wide association studies of bipolar disorder reveals important points of agreement. Mol. Psychiatry 2008, 13:466-467.
10. Benatti P., Dolfini D., Vigano A., Ravo M., Weisz A., Imbriano C. Specific inhibition of NF-Y subunits triggers different cell proliferation defects. Nucleic Acids Res. 2011, 39:5356-5368.
11. Bremer T., Diamond C., McKinney R., Shehktman T., Barrett T.B., Herold C., et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol. Diagn. Ther. 2007, 11:161-170.
12. Broer L., Lill C.M., Schuur M., Amin N., Roehr J.T., Bertram L., et al. Distinguishing true from false positives in genomic studies: p values. Eur. J. Epidemiol. 2013, 28:131-138.
13. Cacabelos R., Martinez-Bouza R., Carril J.C., Fernandez-Novoa L., Lombardi V., Carrera I., et al. Genomics and pharmacogenomics of brain disorders. Curr. Pharm. Biotechnol. 2012, 13:674-725.
14. Cao Q., Martinez M., Zhang J., Sanders A.R., Badner J.A., Cravchik A., et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1997, 43:1-8.
15. Chan H.F., Chen M.L., Su J.J., Ko L.C., Lin C.H., Wu R.M. A novel neuropsychiatric phenotype of KCNJ2 mutation in one Taiwanese family with Andersen-Tawil syndrome. J. Hum. Genet. 2010, 55:186-188.
16. Chen C.H., Lee C.S., Lee M.T., Ouyang W.C., Chen C.C., Chong M.Y., et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N. Engl. J. Med. 2014, 370:119-128.
17. Cherlyn S.Y., Woon P.S., Liu J.J., Ong W.Y., Tsai G.C., Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci. Biobehav. Rev. 2010, 34:958-977.
18. Chiu C., Scheuing L., Liu G., Liao H., Linares G.R., Lin D., et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int. J. Neuropsychopharmacol. 2014, 18:1-13.
19. Consortium on Lithium Genetics, Hou L., Heilbronner U., Rietschel M., Kato T., Kuo P.H., et al. Variant GADL1 and response to lithium in bipolar I disorder. N. Engl. J. Med. 2014, 370:1857-1859.
20. Dalvie S., Horn N., Nossek C., van der Merwe L., Stein D.J., Ramesar R. Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype. Afr. J. Psychiatry (Johannesbg) 2010, 13:297-301.
21. Drago A., Crisafulli C., Serretti A. The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B:975-986.
22. Ewald H., Wang A.G., Vang M., Mors O., Nyegaard M., Kruse T.A. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr. Genet. 1999, 9:23-34.
23. Ewald H., Wikman F.P., Teruel B.M., Buttenschon H.N., Torralba M., Als T.D., et al. A genome-wide search for risk genes using homozygosity mapping and microarrays with 1,494 single-nucleotide polymorphisms in 22 eastern Cuban families with bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 133B:25-30.
24. Fabbri C., Di Girolamo G., Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20years of research. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162B:487-520.
25. Fallin M.D., Lasseter V.K., Avramopoulos D., Nicodemus K.K., Wolyniec P.S., McGrath J.A., et al. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 2005, 77:918-936.
26. Gaudet M.M., Kirchhoff T., Green T., Vijai J., Korn J.M., Guiducci C., et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010, 6.
27. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem. 2002, 80:589-597.
28. Hattori M., Kunugi H., Akahane A., Tanaka H., Ishida S., Hirose T., et al. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am. J. Med. Genet. 2002, 114:304-309.
29. Hisanaga-Oishi Y., Nishiwaki-Ueda Y., Nojima K., Ueda H. Analysis of the expression of candidate genes for type 1 diabetes susceptibility in T cells. Endocr. J. 2014, 61:577-588.
30. Ising M., Lucae S., Binder E.B., Bettecken T., Uhr M., Ripke S., et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 2009, 66:966-975.
31. Jenkins A., Apud J.A., Zhang F., Decot H., Weinberger D.R., Law A.J. Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia. Neuropsychopharmacology 2014, 39:2170-2178.
32. Judy J.T., Zandi P.P. A review of potassium channels in bipolar disorder. Front. Genet. 2013, 4:105.
33. Kim B., Kim C.Y., Lee M.J., Joo Y.H. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 2009, 168:209-212.
34. Kochlamazashvili G., Senkov O., Grebenyuk S., Robinson C., Xiao M.F., Stummeyer K., et al. Neural cell adhesion molecule-associated polysialic acid regulates synaptic plasticity and learning by restraining the signaling through GluN2B-containing NMDA receptors. J. Neurosci. 2010, 30:4171-4183.
35. Leclerc E., Mansur R.B., Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J. Affect. Disord. 2013, 149:247-252.
36. Lee S.Y., Chen S.L., Chang Y.H., Chen S.H., Chu C.H., Huang S.Y., et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J. Affect. Disord. 2012, 138:295-300.
37. Lett T.A., Tiwari A.K., Meltzer H.Y., Lieberman J.A., Potkin S.G., Voineskos A.N., et al. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophr. Res. 2011, 132:121-124.
38. Lorenzi C., Delmonte D., Pirovano A., Marino E., Bongiorno F., Catalano M., et al. Searching susceptibility loci for bipolar disorder: a sib pair study on chromosome 12. Neuropsychobiology 2010, 61:10-18.
39. Lu Y., Wang C., Xue Z., Li C., Zhang J., Zhao X., et al. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice involve in the rapid onset antidepressant-like effects of GLYX-13. Int. J. Neuropsychopharmacol. 2014, 18:1-12.
40. Luoni A., Macchi F., Papp M., Molteni R., Riva M.A. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int. J. Neuropsychopharmacol. 2014, 18:1-12.
41. Masui T., Hashimoto R., Kusumi I., Suzuki K., Tanaka T., Nakagawa S., et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int. J. Neuropsychopharmacol. 2006, 9:83-88.
42. McGuffin P., Rijsdijk F., Andrew M., Sham P., Katz R., Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry 2003, 60:497-502.
43. Milton A.C., Packard A.V., Clary L., Okkema P.G. The NF-Y complex negatively regulates Caenorhabditis elegans tbx-2 expression. Dev. Biol. 2013, 382:38-47.
44. Morelli C., Magnanini C., Mungall A.J., Negrini M., Barbanti-Brodano G. Cloning and characterization of two overlapping genes in a subregion at 6q21 involved in replicative senescence and schizophrenia. Gene 2000, 252:217-225.
45. Murai-Takeda A., Shibata H., Kurihara I., Kobayashi S., Yokota K., Suda N., et al. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J. Biol. Chem. 2010, 285:8084-8093.
46. O'Dushlaine C., Kenny E., Heron E., Donohoe G., Gill M., Morris D., et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol. Psychiatry 2011, 16:286-292.
47. Ollila H.M., Soronen P., Silander K., Palo O.M., Kieseppa T., Kaunisto M.A., et al. Findings from bipolar disorder genome-wide association studies replicate in a Finnish bipolar family-cohort. Mol. Psychiatry 2009, 14:351-353.
48. Park S.W., Lee J.G., Seo M.K., Lee C.H., Cho H.Y., Lee B.J., et al. Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. Int. J. Neuropsychopharmacol. 2014, 17:1831-1846.
49. Perlis R.H., Smoller J.W., Ferreira M.A., McQuillin A., Bass N., Lawrence J., et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry 2009, 166:718-725.
50. Piazza L., Fishman G.A., Kaplan R.D., Horowitz A.L., Hindo W.A., Mafee M.F. Magnetic resonance imaging of central nervous system defects in Usher's syndrome. Retina 1987, 7:241-245.
51. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., Santucci V., et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007, 32:17-34.
52. Post R.M., Leverich G.S., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., et al. Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J. Clin. Psychiatry 2012, 73:924-930.
53. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
54. Rybakowski J.K. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs 2013, 27:165-173.
55. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 2003, 53:1028-1042.
56. Sachs G.S., Peters A.T., Sylvia L., Grunze H. Polypharmacy and bipolar disorder: what's personality got to do with it?. Int. J. Neuropsychopharmacol. 2014, 17:1053-1061.
57. Saur T., DeMarco S.E., Ortiz A., Sliwoski G.R., Hao L., Wang X., et al. A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target. PLoS Genet. 2013, 9.
58. Schosser A., Gaysina D., Cohen-Woods S., Domenici E., Perry J., Tozzi F., et al. A follow-up case-control association study of tractable (druggable) genes in recurrent major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B:640-650.
59. Schulze T. The Consortium on Lithium Genetics (ConLiGen) Genome-wide Association Studies of Lithium Response Phenotypes in Bipolar Disorder 2012, 36. CINP Congress, Stockholm.
60. Schulze T.G., Alda M., Adli M., Akula N., Ardau R., Bui E.T., et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010, 62:72-78.
61. Shaltiel G., Chen G., Manji H.K. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr. Opin. Pharmacol. 2007, 7:22-26.
62. Shanker V., Groves M., Heiman G., Palmese C., Saunders-Pullman R., Ozelius L., et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov. Disord. 2011, 26:1875-1880.
63. Sklar P., Smoller J.W., Fan J., Ferreira M.A., Perlis R.H., Chambert K., et al. Whole-genome association study of bipolar disorder. Mol. Psychiatry 2008, 13:558-569.
64. Smith E.N., Bloss C.S., Badner J.A., Barrett T., Belmonte P.L., Berrettini W., et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol. Psychiatry 2009, 14:755-763.
65. Soler-Alfonso C., Carvalho C.M., Ge J., Roney E.K., Bader P.I., Kolodziejska K.E., et al. CHRNA7 triplication associated with cognitive impairment and neuropsychiatric phenotypes in a three-generation pedigree. Eur. J. Hum. Genet. 2014, 22:1071-1076.
66. Song G.G., Lee Y.H. Pathway analysis of genome-wide association studies for Parkinson's disease. Mol. Biol. Rep. 2013, 40:2599-2607.
67. Squassina A., Manchia M., Borg J., Congiu D., Costa M., Georgitsi M., et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 2011, 12:1559-1569.
68. Tadokoro K., Hashimoto R., Tatsumi M., Kamijima K., Kunugi H. Analysis of enhancer activity of a dinucleotide repeat polymorphism in the neurotrophin-3 gene and its association with bipolar disorder. Neuropsychobiology 2004, 50:206-210.
69. Takata A., Kawasaki H., Iwayama Y., Yamada K., Gotoh L., Mitsuyasu H., et al. Nominal association between a polymorphism in DGKH and bipolar disorder detected in a meta-analysis of East Asian case-control samples. Psychiatry Clin. Neurosci. 2011, 65:280-285.
70. Tansey K.E., Rucker J.J., Kavanagh D.H., Guipponi M., Perroud N., Bondolfi G., et al. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics J. 2014, 14:395-399.
71. Thomsen M.S., Weyn A., Mikkelsen J.D. Hippocampal alpha7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disord. 2011, 13:701-707.
72. Tomas C., Canellas F., Rodriguez V., Picornell A., Lafau O., Nadal M., et al. Genetic linkage study for bipolar disorders on chromosomes 17 and 18 in families with a high expression of mental illness from the Balearic Islands. Psychiatr. Genet. 2006, 16:145-151.
73. Turecki G., Grof P., Grof E., D'Souza V., Lebuis L., Marineau C., et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry 2001, 6:570-578.
74. Wang Z., Fan J., Gao K., Li Z., Yi Z., Wang L., et al. Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder. J. Mol. Neurosci. 2013, 50:305-310.
75. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
76. Winkler C., Krumsiek J., Buettner F., Angermuller C., Giannopoulou E.Z., Theis F.J., et al. Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes. Diabetologia 2014, 57:2521-2529.
77. Yun D.H., Pae C.U., Drago A., Mandelli L., De Ronchi D., Patkar A.A., et al. Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. Psychiatry Investig. 2008, 5:102-105.
78. Zhu Q., Wang L., Xiao Z., Xiao F., Luo J., Zhang X., et al. Decreased expression of Ras-GRF1 in the brain tissue of the intractable epilepsy patients and experimental rats. Brain Res. 2013, 1493:99-109.
79. Zuberi K., Franz M., Rodriguez H., Montojo J., Lopes C.T., Bader G.D., et al. GeneMANIA prediction server 2013 update. Nucleic Acids Res. 2013, 41:W115-W122.